Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.
Shaolong Cao,Jennifer R. Wang,Shuangxi Ji,Peng Yang,Yaoyi Dai,Shuai Guo,Matthew D. Montierth,John Paul Shen,Xiao Zhao,Jingxiao Chen,Jaewon James Lee,Paola A. Guerrero,Nicholas Spetsieris,Nikolai Engedal,Sinja Taavitsainen,Kaixian Yu,Julie Livingstone,Vinayak Bhandari,Shawna M. Hubert,Najat C. Daw,P. Andrew Futreal,Eleni Efstathiou,Bora Lim,Andrea Viale,Jianjun Zhang,Matti Nykter,Bogdan A. Czerniak,Powel H. Brown,Charles Swanton,Pavlos Msaouel,Anirban Maitra,Scott Kopetz,Peter Campbell,Terence P. Speed,Paul C. Boutros,Hongtu Zhu,Alfonso Urbanucci,Jonas Demeulemeester,Peter Van Loo,Wenyi Wang
DOI: https://doi.org/10.1038/s41587-022-01342-x
IF: 46.9
2022-06-16
Nature Biotechnology
Abstract:Single-cell RNA sequencing studies have suggested that total mRNA content correlates with tumor phenotypes. Technical and analytical challenges, however, have so far impeded at-scale pan-cancer examination of total mRNA content. Here we present a method to quantify tumor-specific total mRNA expression (TmS) from bulk sequencing data, taking into account tumor transcript proportion, purity and ploidy, which are estimated through transcriptomic/genomic deconvolution. We estimate and validate TmS in 6,590 patient tumors across 15 cancer types, identifying significant inter-tumor variability. Across cancers, high TmS is associated with increased risk of disease progression and death. TmS is influenced by cancer-specific patterns of gene alteration and intra-tumor genetic heterogeneity as well as by pan-cancer trends in metabolic dysregulation. Taken together, our results indicate that measuring cell-type-specific total mRNA expression in tumor cells predicts tumor phenotypes and clinical outcomes.
biotechnology & applied microbiology